|
|
|
LifeScienceHistory.com - Check us out on Instagram
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Mirati Therapeutics
| | | Phone: | (858) 332-3410 | Year Established: | 1995 | Ticker: | MRTX | Exchange: | NASDAQ | Main Contact: | Jessica M. Corson, MBA, Director, Business Development | | Other Contacts: | Chris LeMasters, Executive VP and CBO Perry C. Johnston, VP, Legal Jamie Donadio, Senior VP & CFO James Christensen, Ph.D., Senior VP & CSO Charles M. Baum, MD, Ph.D., President & CEO Isan Chen, MD, Chief Medical & Development Officer
| | Company Description | Mirati Therapeutics is a targeted oncology company developing an advanced pipeline of breakthrough medicines for precisely defined patient populations. Mirati's approach combines the three most important factors in oncology drug development - drug candidates with complementary and compelling targets, creative and agile clinical development, and a highly accomplished precision medicine leadership team. The Mirati team is using its proven blueprint for developing targeted oncology medicines to advance and maximize the value of its pipeline of drug candidates, including MGCD265 and MGCD516, which are orally bioavailable, multi-targeted kinase inhibitors with distinct target profiles, and mocetinostat, an orally bio-available, spectrum-selective histone deacetylase inhibitor. | |
|
|
|
|
|